Anxiolytic Therapy with Lorazepam and Clonazepam

Pharmacokinetic Considerations

Lorazepam has an intermediate half-life of 8-15 hours with no active metabolites, providing more predictable effects and easier dose titration 1, 2
Clonazepam has a long half-life of 30-40 hours, allowing for once or twice daily dosing but increasing risk of drug accumulation and prolonged sedation 1
Lorazepam undergoes direct glucuronidation with no active metabolites, making it safer in patients with renal failure 3, 1
Benzodiazepine clearance decreases with age, making clonazepam's prolonged effects more pronounced in elderly patients 3, 1

The American College of Critical Care Medicine recommends lorazepam as the preferred benzodiazepine due to predictable duration and safety profile 2
The American Academy of Sleep Medicine supports clonazepam use for panic disorder at doses of 0.25-2.0 mg (up to 4.0 mg reported) 1
The American Geriatrics Society recommends caution with all benzodiazepines due to increased risk of confusion, ataxia, and falls; clonazepam's long half-life poses particular risk 1, 2

Parenteral lorazepam formulations contain propylene glycol as a diluent, which can cause metabolic acidosis and acute kidney injury 3, 2
Toxicity can occur with total daily IV doses as low as 1 mg/kg (not just high-dose continuous infusions) 3
Monitor serum osmol gap; values >10-12 mOsm/L suggest significant propylene glycol accumulation 3
Both lorazepam and clonazepam carry risk of paradoxical rage reactions in pediatric patients 4, 5
Both agents cause dose-dependent respiratory depression, especially when combined with opioids or alcohol 1, 2

Lorazepam allows for flexible titration given shorter half-life 2
Clonazepam dosing is 0.25-2.0 mg for anxiety/panic disorder (up to 4.0 mg reported), with once or twice daily administration 1
Overlooking renal function can lead to accumulation of clonazepam and other long-acting benzodiazepines; lorazepam is safer but still requires propylene glycol monitoring 3, 2